Outpoll Weekly Recap: Science (October 27 – November 2, 2025)

4 hours ago7 min read2 comments

This week, the science sector felt less like a steady march of progress and more like a series of quantum leaps, with prediction markets scrambling to price in paradigm-shifting announcements. The biotech arena was electric, as a Phase III trial for a novel CRISPR-based therapeutic targeting a hereditary form of cardiomyopathy posted staggering interim efficacy data, causing the lead firm's stock and associated prediction contracts on its eventual FDA approval to surge by over 40%.This isn't just another drug candidate; it's a validation of in-vivo gene editing's potential to move from rare monogenic disorders to more common, complex conditions, rewriting the entire playbook for cardiovascular medicine. Simultaneously, the AI-for-science space witnessed its own seismic event, with a research consortium open-sourcing a large language model specifically trained on molecular biology and chemical synthesis data.Early benchmarks suggest it can drastically accelerate drug discovery pipelines, and markets are now actively betting on which major pharma giant will be the first to license the technology for a blockbuster application, with Novartis currently holding a narrow lead. On the climate front, a successful pilot of a direct air capture facility in Iceland, which achieved a new benchmark in cost-per-tonne of CO2 captured, sent ripples through green tech markets.While still nascent, the project's success has fueled a 25% uptick in contracts predicting that a DAC-based carbon removal credit will be traded on a major commodities exchange within the next 18 months. The week underscored a clear trend: the convergence of biology, computation, and climate engineering is no longer a futuristic concept but the dominant driver of scientific and market momentum, with each breakthrough creating a cascade of new, high-stakes predictions about our technological future.

#Weekly recap